keyword
MENU ▼
Read by QxMD icon Read
search

Cardio oncology

keyword
https://www.readbyqxmd.com/read/28330818/cardio-onco-hematology-in-clinical-practice-position-paper-and-recommendations
#1
Teresa López-Fernández, Ana Martín García, Ana Santaballa Beltrán, Ángel Montero Luis, Ramón García Sanz, Pilar Mazón Ramos, Sonia Velasco Del Castillo, Esteban López de Sá Areses, Manuel Barreiro-Pérez, Rocío Hinojar Baydes, Leopoldo Pérez de Isla, Silvia Cayetana Valbuena López, Regina Dalmau González-Gallarza, Francisco Calvo-Iglesias, Juan José González Ferrer, Antonio Castro Fernández, Eva González-Caballero, Cristina Mitroi, Meritxell Arenas, Juan Antonio Virizuela Echaburu, Pascual Marco Vera, Andrés Íñiguez Romo, José Luis Zamorano, Juan Carlos Plana Gómez, José Luis López Sendón Henchel
Improvements in early detection and treatment have markedly reduced cancer-related mortality. However survival not only depends on effectively cure cancer, but prevention, diagnosis and treatment of cancer-related complications is also needed. Cardiovascular toxicity is a widespread problem across many classes of therapeutic schemes, however scientific evidence in the management of cardiovascular complications of onco-hematological patients is scarce, as these patients have been systematically excluded from clinical trials and current recommendations are based on expert consensus...
March 18, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28330611/rationale-for-cardio-oncology-units
#2
Lara F Nhola, Hector R Villarraga
With the rapidly rising number of patients surviving cancer, often in the setting of new or pre-existing cardiovascular disease and risk factors, a need has arisen for a specialty within the realm of cardiovascular care that can evaluate and manage these patients along with our colleagues in oncology and hematology. By the same token, all health care providers involved in the care of cancer patients with heart disease must be fully aware of the impact of adverse cardiovascular effects on the survival of these patients...
March 16, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28320853/cardio-oncology-vascular-endothelial-growth-factor-inhibitors-salt-and-macrophages-a-complicated-interaction
#3
Javid Moslehi, Arvind K Pandey, Nirmanmoh Bhatia
No abstract text is available yet for this article.
March 20, 2017: Hypertension
https://www.readbyqxmd.com/read/28316172/-cardio-oncology-in-the-bud-opportunities-and-challenges
#4
Y L Xia, Y Zhang
No abstract text is available yet for this article.
March 24, 2017: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/28315122/cardio-oncology-the-nuclear-option
#5
REVIEW
Jorge A Alvarez, Raymond R Russell
PURPOSE OF REVIEW: Cardio-oncology focuses increased effort to decrease cancer treatment-related cardiotoxicity while continuing to improve outcomes. We sought to synthesize the latest in nuclear cardiology as it pertains to the assessment of left ventricular function in preventative guidelines and comparison to other modalities, novel molecular markers of pre-clinical cardiotoxicity, and its role in cardiac amyloid diagnosis. RECENT FINDINGS: Planar ERNA (equilibrium radionuclide angiocardiography) provides a reliable and proven means of monitoring and preventing anthracycline cardiotoxicity, and SPECT ERNA using solid-state gamma cameras may provide reproducible assessments of left ventricular function with reduced radiation exposure...
April 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28314336/cardio-oncology-1st-edition
#6
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28297727/new-knowledge-about-old-drugs-the-anti-inflammatory-properties-of-cardiac-glycosides
#7
Robert Fürst, Ilse Zündorf, Theo Dingermann
In the 19th century, cardio-active steroid glycosides, shortly cardiac glycosides, were scientifically established as drugs against heart failure. Their in vivo, cellular, and molecular actions as well as their predominant target, Na(+)-K(+)-ATPase, have been comprehensively investigated in the 20th century and the discovery of endogenous cardiac glycosides has fostered this research field. In the last years, however, results from clinical trials and meta-analyses have questioned their therapeutic value due to efficacy and safety issues...
March 15, 2017: Planta Medica
https://www.readbyqxmd.com/read/28287211/-anmco-aico-aiom-consensus-document-clinical-and-management-pathways-in-cardio-oncology
#8
Luigi Tarantini, Michele Massimo Gulizia, Andrea Di Lenarda, Nicola Maurea, Maurizio Giuseppe Abrignani, Irma Bisceglia, Daniella Bovelli, Luisa De Gennaro, Donatella Del Sindaco, Francesca Macera, Iris Parrini, Donatella Radini, Giulia Russo, Angela Beatrice Scardovi, Alessandro Inno
In Italy, cardiovascular diseases and cancer are the leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced survival of cancer patients registered in the last decades and linked to early diagnosis and improvement of care, not infrequently exposes them to the appearance of ominous cardiovascular complications due to the deleterious effects of cancer treatment on the heart and circulatory system...
January 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28285949/considerations-in-cardio-oncology-multiple-mobile-left-sided-cardiac-thrombi-in-chemotherapy-induced-cardiomyopathy
#9
Toshinori Minamishima, Kenichi Matsushita, Hiromu Morikubo, Aoi Isaka, Noriko Matsushita, Hidehito Endo, Hiroshi Kubota, Konomi Sakata, Toru Satoh, Hideaki Yoshino
With advances in cancer chemotherapy, the importance of the new clinical discipline of cardio-oncology, which is concerned with the cardiac effects of chemotherapy, is increasing. Herein we describe the case of a 48-year-old woman with a history of breast cancer who presented with symptoms of heart failure due to chemotherapy-induced cardiomyopathy. Treatment for the patient's breast cancer had included surgery and chemotherapy with anthracyclines and trastuzumab. Echocardiography revealed multiple mobile thrombi in the left ventricle and atrium...
March 10, 2017: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28284844/investigating-methotrexate-toxicity-within-a-randomized-double-blinded-placebo-controlled-trial-rationale-and-design-of-the-cardiovascular-inflammation-reduction-trial-adverse-events-cirt-ae-study
#10
Jeffrey A Sparks, Medha Barbhaiya, Elizabeth W Karlson, Susan Y Ritter, Soumya Raychaudhuri, Cassandra C Corrigan, Fengxin Lu, Jacob Selhub, Daniel I Chasman, Nina P Paynter, Paul M Ridker, Daniel H Solomon
BACKGROUND: The role of low dose methotrexate (LDM) in potential serious toxicities remains unclear despite its common use. Prior observational studies investigating LDM toxicity compared LDM to other active drugs. Prior placebo-controlled clinical trials of LDM in inflammatory conditions were not large enough to investigate toxicity. The Cardiovascular Inflammation Reduction Trial (CIRT) is an ongoing NIH-funded, randomized, double-blind, placebo-controlled trial of LDM in the secondary prevention of cardiovascular disease...
February 10, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28279426/cardio-oncology-a-rapidly-evolving-and-expanding-field-of-medicine
#11
EDITORIAL
Daniel J Lenihan, Douglas B Sawyer
No abstract text is available yet for this article.
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279424/cardio-oncology-the-role-of-big-data
#12
REVIEW
Anant Mandawat, Andrew E Williams, Sanjeev A Francis
Despite its challenges, a "big data" approach offers a unique opportunity within the field of cardio-oncology. A pharmacovigilant approach using large data sets can help characterize cardiovascular toxicities of the rapidly expanding armamentarium of targeted therapies. Creating a broad coalition of data sharing can provide insights into the incidence of cardiotoxicity and stimulate research into the underlying mechanisms. Population health necessitates the use of big data and can help inform public health interventions to prevent both cancer and cardiovascular disease...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279422/cardio-oncology-related-to-heart-failure-common-risk-factors-between-cancer-and-cardiovascular-disease
#13
REVIEW
Anne Blaes, Anna Prizment, Ryan J Koene, Suma Konety
There is a growing body of evidence that suggests cancer and cardiovascular disease have a shared biological mechanism. Although there are several shared risk factors for both diseases, including advancing age, gender, obesity, diabetes, physical activity, tobacco use, and diet, inflammation and biomarkers, such as insulinlike growth factor 1, leptin, estrogen, and adiponectin, may also play a role in the biology of these diseases. This article provides an overview of the shared biological mechanism between cancer and cardiovascular disease...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279421/how-to-develop-a-cardio-oncology-fellowship
#14
REVIEW
Michelle N Johnson, Richard Steingart, Joseph Carver
Management of cardiovascular disease in patients with cancer and cancer survivors requires particular clinical expertise and skills that are central to cardio-oncology. The areas of knowledge required include specific cardiovascular complications directly related to oncologic therapies and the impact of cancer and its therapies on existing or potential cardiovascular comorbidities. Many cancer therapeutics have potential cardiotoxicity. The conversion of many cancers to chronic conditions, rather than fatal diseases, has produced a population of patients with cancer at high risk for cardiovascular diseases that require specialized knowledge of treating physicians...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279420/how-to-develop-a-cardio-oncology-clinic
#15
REVIEW
David Snipelisky, Jae Yoon Park, Amir Lerman, Sharon Mulvagh, Grace Lin, Naveen Pereira, Martin Rodriguez-Porcel, Hector R Villarraga, Joerg Herrmann
Cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. As a consequence, interactions with cardiovascular disease specialists have intensified to the point of the development of a new discipline termed cardio-oncology. As an additional consequence, so-called cardio-oncology clinics have emerged, in most cases staffed by cardiologists with an interest in the field. This article addresses this gap and summarizes key points in the development of a cardio-oncology clinic...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279417/cardio-oncology-related-to-heart-failure-pediatric-considerations-for-cardiac-dysfunction
#16
REVIEW
Kirsten Rose-Felker, William L Border, Borah J Hong, Eric J Chow
Although tremendous advances in pediatric cancer treatment have improved the survival of many children, these patients remain at increased risk of early morbidity and mortality with cardiovascular disease as a leading cause of death. Heightened awareness in providers with increased surveillance and improvement in cardiovascular imaging modalities have led to earlier detection of cardiac dysfunction, but the outcomes remain poor once this has dysfunction developed. A great deal of work remains to be done to refine screening and identify high-risk patients more precisely, and to develop more evidence-based strategies for effective primary and secondary cardioprotection and treatment...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279416/cardio-oncology-related-to-heart-failure-epidermal-growth-factor-receptor-target-based-therapy
#17
REVIEW
Benjamin Kenigsberg, Varun Jain, Ana Barac
Cancer therapy targeting the epidermal growth factor receptor (EGFR)/erythroblastic leukemia viral oncogene B (ErbB)/human EGFR receptor (HER) family of tyrosine kinases has been successfully used in treatment of several malignancies. The ErbB pathways play a role in the maintenance of cardiac homeostasis. This article summarizes current knowledge about EGFR/ErbB/HER receptor-targeted cancer therapeutics focusing on their cardiotoxicity profiles, molecular mechanisms, and implications in clinical cardio-oncology...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28268088/acute-decompensated-heart-failure-as-a-reason-of-premature-chemotherapy-discontinuation-may-be-independent-of-a-lifetime-doxorubicin-dose-in-lymphoma-patients-with-cardiovascular-disorders
#18
Sebastian Szmit, Wojciech Jurczak, Jan Maciej Zaucha, Monika Długosz-Danecka, Barbara Sosnowska-Pasiarska, Ewa Chmielowska, Monika Joks, Joanna Drozd-Sokołowska, Wanda Knopińska-Posłuszny, Wojciech Spychałowicz, Beata Kumiega, Grzegorz Charliński, Marta Morawska, Grzegorz Słomian
BACKGROUND: Algorithm of anthracycline-based chemotherapy with favourable cardio-oncological outcome should be clearly re-defined for lymphoma patients with significant pre-existing cardiovascular diseases. A clinical benefit of liposomal forms of anthracycline is still debatable. METHODS: Polish registry included observations of 138 lymphoma patients with concomitant cardiovascular disorders who received liposomal doxorubicin as cardioprotective alternative of conventional form...
February 22, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28264617/integrated-cardiovascular-safety-multifaceted-considerations-in-drug-development-and-therapeutic-use
#19
J Rick Turner
Cardiovascular safety has become a central component of contemporary drug development and therapeutic use since noncardiovascular drugs can exert cardiovascular harms. Appropriate preapproval investigations and monitoring during clinical practice are therefore advantageous. Areas covered: Integrated cardiovascular safety is a broad field of investigation. This review focuses on three areas of assessment specifically chosen to exemplify advances and challenges in this field: the cardiotoxicity of oncologic agents, off-target blood pressure (BP) increases to noncardiovascular drugs, and the cardiovascular safety of new antidiabetic drugs for type 2 diabetes (T2D)...
March 6, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28254996/cardio-oncology-what-you-need-to-know-now-for-clinical-practice-and-echocardiography
#20
REVIEW
Charlotte M Larsen, Sharon L Mulvagh
Cardio-oncology is a rapidly growing field aimed at minimizing the effects of cardiovascular morbidity and mortality in cancer survivors. To meet this aim, patients are assessed at baseline to define their risk of cardiotoxicity and then followed closely during and after chemotherapy to assess for early signs or symptoms of cardiovascular disease. Cardiac imaging, and in particular transthoracic echocardiography, plays an essential role in the baseline assessment and serial follow-up of cardio-oncology patients...
March 2, 2017: Echo Research and Practice
keyword
keyword
4685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"